SGMT
USDSagimet Biosciences Inc. Series A Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$7.530
Kõrge
$7.670
Madal
$7.020
Maht
0.13M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
244.6M
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
0.57M
Börs
NGM
Valuuta
USD
52 nädala vahemik
Seotud uudised
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical trial in acne in China conducted by license partner Ascletis Ascletis announced completion of
Clear Street Initiates Coverage On Sagimet Biosciences with Buy Rating, Announces Price Target of $29
Clear Street analyst Kaveri Pohlman initiates coverage on Sagimet Biosciences with a Buy rating and announces Price Target of $29.
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
SAN MATEO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
SAN MATEO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.